Immunic Secures U.S. Patent for Vidofludimus Calcium in Multiple Sclerosis

Immunic, Inc. has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering dose strengths of its lead drug, vidofludimus calcium, in the treatment of progressive multiple sclerosis. The patent extends protection in the U.S. through 2041, with the possibility of further extensions.

Vidofludimus calcium is under development as a treatment for chronic inflammatory and autoimmune diseases. Recent phase 2 trial results demonstrated its potential in delaying disability worsening for multiple sclerosis patients, supporting its potential to slow disease progression.

The new patent strengthens Immunic's intellectual property portfolio, as the company plans further discussions with healthcare authorities to advance vidofludimus calcium towards market availability.